by Floyd County Schools reports Rn T.Com

With small class sizes, the highly-selective courses in the Duke program are very competitive with limited availability. Just to be eligibility for enrollment is an honor and indicates the student has exhibited outstanding intellectual ability and dedication to academics. Duke TIP provides participants with an exciting, stimulating and challenging opportunity to augment their interests and capabilities. Through a variety of experiential activities, lab work, discussions, fieldwork, collaboration, presentations, and the use of advanced technology and lab equipment, participants in the genetics program will delve into cutting-edge human genetic research. Topics included in the program are: human gene expression, pharmacogenomics, and epigenetic control of DNA, SNP genotyping, gene sequencing, forensic biology, and medical genetics. Hosmer's experience will culminate with the creation of an individual laboratory project that she will present to Duke faculty and her institute peers.

At Armuchee High School, Hosmer is involved with the National Honors Society and Academic Decathlon and she has maintained a 4.0 GPA. Hosmer also volunteers in the community at Mount Berry Animal Hospital and the Rome Action Ministries Food Pantry. She plans to pursue undergraduate degrees in Biology and Veterinarian Sciences at Berry College or at the University of Georgia before deciding upon a school of medicine.

Click here to read additional press releases on RN-T.com.

See original here:
Armuchee junior to study human genetics at Duke University this summer

ROCHESTER, N.Y.--(BUSINESS WIRE)--

ACM Global Central Lab, the central laboratory that continually defines the customer-service standard with its flexible approach, is pleased to announce that Mark Engelhart has joined the executive management team as chief commercial officer. Engelhart will be responsible for leading ACM Globals business development, proposals and contracts, marketing and sales activities worldwide.

Prior to joining ACM Global, Engelhart was chief commercial officer at Cryoport, Inc. a provider of leading-edge cold chain logistics services. His experience also includes serving in varying sales and marketing management and operations roles at leading pharmaceutical companies, including Bayer and Abbot Laboratories. Engelhart has also held the role of vice president of global sales and marketing at Covance Laboratory, Quest Diagnostics Clinical Trials division and Esoterix Clinical Trials Services.

We are extremely pleased to have Mark join ACM Global, said Angela J. Panzarella, president of ACM Global Central Lab. Mark is a highly accomplished senior executive with deep experience in sales, marketing, strategy, and global commercial operations for central laboratory services and clinical trials support services, and will be a valuable addition to our executive team.

ACM Global will be on hand to discuss the latest trends in clinical research lab testing at PCMG Annual Conference, June 13-15 at the Pine Cliffs Hotel in Portugal and at the 48th Annual DIA Meeting, June 24-28 in Philadelphia.

About ACM Global Central Lab

ACM Global Central Lab offers a flexible approach and a focus on precision to keep clinical research studies on schedule. ACM Globals services extend to more than 60 countries with all tests conducted and managed from central lab facilities with seamless data management providing a single database. The organization performs 14 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.

For more information, visit http://www.acmgloballab.com, our Central Labs in Focus blog or call +1 866 405 0400.

See the rest here:
ACM Global Central Laboratory Appoints Mark Engelhart as Chief Commercial Officer

BELTSVILLE, MD--(Marketwire -05/16/12)- BioServe today announced that the Ventyx Wesley Research Institute Tissue Bank, the largest state-of-the-art bio-repository of human tissue and blood in Queensland, Australia, has joined BioServe's network of affiliated bio-repositories. As part of the BioServe Network, the Ventyx Wesley Research Institute Tissue Bank will make available its high volume of oncology tissue and blood samples to industry and academic researchers worldwide. The collaborative partnership between BioServe and the Wesley Research Institute was facilitated by Bio-Link Australia Pty. Ltd., a life sciences commercialisation company.

The Ventyx Wesley Research Institute Tissue Bank joins the growing BioServe Network that includes Fox Chase Cancer Center, University of Massachusetts Medical School, the Windber Research Institute, and Maine Medical Center. The Network, along with BioServe's Global BioRepository, creates the largest commercial-ready specimen repository in the world with over 2 million samples in most major diseases. Such specimens hold the data driving genetic and biomarker discovery and validation for effective patient stratification, drug discovery and development of new diagnostics.

The Ventyx Wesley Research Institute Tissue Bank was founded in 2007 and is a purpose-built research facility established to provide a diverse collection of ethically obtained tissue specimens for biomedical research. The Tissue Bank operates at the Wesley Research Institute, which is located on the Wesley Hospital campus in Auchenflower, Brisbane. It collects and stores tissue samples, blood and related clinical data from consenting patients at The Wesley Hospital and makes these specimens and clinical data available to ethically approved medical researchers. The Tissue Bank adheres to the international standards set down in Good Clinical Practice and Good Laboratory Practice guidelines.

"We are pleased that the Ventyx Wesley Research Institute Tissue Bank will make its high quality tissue samples available through the BioServe Network. By tapping this unique and comprehensive sample resource, researchers can quickly obtain most any type of human biological sample in most any disease," said Rama Modali, President of BioServe.

"Becoming part of the BioServe Network will enable us to reach a greater proportion of the scientific research community, putting our samples into the hands of researchers developing new therapies and diagnostics," said Dr. Greg Hafner, Chief Operations Officer of the Wesley Research Institute.

About BioServe BioServe provides a comprehensive 'biomaterial to validated data' genomics services platform, helping researchers gain the pre-clinical data for breakthroughs in drug discovery, molecular diagnostics and pharmacogenomics. Utilizing BioServe's genomics services platform, researchers can identify genetic markers, validate drug targets and correlate clinical data with molecular data to accelerate the development of new and safer drugs. BioServe's services extend from nucleic acids processing, DNA synthesis, high throughput genotyping, genome wide-scans and gene expression analyses to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and many cancers. BioServe's Global BioRepository provides researchers with a library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients from four continents.

For more information please visit http://www.bioserve.com or call 301-470-3362.

About Wesley Research InstituteThe Wesley Research Institute is an independent, not-for-profit medical research organisation that conducts research focusing on improving patient care and quality of life. Its clinical and applied research aims to discover, test and refine new techniques for better diagnosis and treatment of illness and disease that work towards its motto of 'making a difference today.' Wesley Research Institute provides a range of scientific services across three main areas -- Investigative Research, Clinical Trials and Tissue Banking.

For more information please visit http://www.wesleyresearch.org.au or email enquiries@wesleyresearch.com.au.

About Bio-Link AustraliaBio-Link Australia Pty. Ltd., with offices in Melbourne and Sydney, is a life sciences commercialisation company offering professional business development services to facilitate commercial partnerships in the biopharmaceutical and diagnostic industries. Bio-Link's clients include leading biotechnology companies and medical research institutes located in Australia and around the world. For more information please visit http://www.bio-link.com.

See the rest here:
The Ventyx Wesley Research Institute Tissue Bank Joins the BioServe Network

OMAHA, Neb.--(BUSINESS WIRE)--

Transgenomic, Inc. (OTCBB: TBIO.OB - News) today reported financial results for the three months ended, March 31, 2012, and provided a business update.

We made progress in the first quarter validating and advancing several of our new high-value products, including the NuclearMitome Test, ICE COLD-PCR in circulating tumor cells and PGxPredict:CLOPIDOGREL response panel, said Craig Tuttle, President and Chief Executive Officer. Our investment in these groundbreaking new products and technologies will fuel growth over the long term and keep Transgenomic at the forefront of the pharmacogenomics and molecular diagnostics industry. Most notably, we continue to build momentum in building awareness around our proprietary, two gene clopidogrel response panel, a test which represents a potential multi-billion dollar market opportunity.

Mr. Tuttle added, Supporting our strategic initiatives was a $22 million private placement financing executed in the first quarter. Together with our focus on the successful development of new products and technologies, and the expansion of our commercial products into new markets, we believe Transgenomic has the strategy, balance sheet strength and operational infrastructure to achieve significant value creation.

Recent Corporate and Business Events

First Quarter Financial Results

Net sales for the first quarter of 2012 were $7.2 million compared with $7.5 million for the same period in 2011. Gross profit was $3.1 million or 43 percent of net sales, compared with gross profit of $4.2 million or 56 percent of net sales for the same period in 2011.

The decrease in revenue is primarily due to a software failure that temporarily resulted in reduced sample processing capacity at the Companys New Haven, Connecticut laboratory testing facility. The Company believes that full sample processing capacity has been restored and expects to complete the sample backlog caused by the LIMS failure by June 2012 in addition to processing the entire volume of samples received during the second quarter. This revenue decrease was partially offset by an increase in instrument deliveries during the quarter.

Operating expenses were $5.5 million during the first quarter of 2012, compared with $4.9 million in the prior year. The largest increase is the recognition of stock options granted in 2011.

The net loss for the first quarter of 2012 was $2.7 million or $0.05 per share compared with a net loss of $2.8 million or $0.06 per share for the first quarter of 2011.

Read more from the original source:
Transgenomic Reports First Quarter 2012 Financial Results

IRVINE, Calif., May 7, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory has entered into a contractual agreement for ancillary diagnostics laboratory testing as a participating provider with TRPN and its 10 million lives network.

Three Rivers Provider Network (TRPN) was founded in 1996 as a company that was contracted to provide services for several major clients. At that time, its clients needed to access a network that would grant PPO type discounts without incurring balance billing risks for their members. Over time, given superior results and the high levels of satisfaction of service that were achieved, TRPN was prompted by other companies that focused on group health and workers compensation to perform similar type services for them.

Since that time, TRPN has evolved into the largest and fastest growing proprietary PPO network in the United States. The TRPN network is now comprised of more than 600,000 total providers, including more than 5,000 hospitals and 70,000 ancillary facilities. Through its clients, approximately 10 million lives now have access to the TRPN PPO network.

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests.The biotechnology company specializes in developing proprietary diagnostic teststhat will assist in identifying patientswho are truly at high risk for the development of a cardiac event.Aviir's proprietary MiRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years.Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders including pharmacogenomics and genetic tests. http://www.aviir.com

"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir.

"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reducing their risk of heart attacks, and decreasing the overall cost of care," Dr. Harrington added.

Learn more at http://www.aviir.com Learn more at http://www.trpnppo.com

For more information: Dina Scaglione Marketing, Communications Manager Dina.Scaglione@aviir.com

View original post here:
Aviir Laboratories Announce National Agreement with Three Rivers Provider Network

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

See original here:
A Conversation with CeGaT's Saskia Biskup

MASON, Ohio, May 7, 2012 /PRNewswire/ --AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.

GeneSightRx ADHD analyzes variations in three genes that influence how a patient might metabolize certain medications used to treat ADHD in children and adults. Understanding a patient's unique genomic profile may help a clinician individualize a patient's medication selection and avoid side effects that often occur with these medications. The test provides objective, evidence-based information for clinicians to personalize medication selection for each patient.

The GeneSightRx ADHD analysis is based on pharmacogenomics, FDA-approved manufacturer's drug labels, published peer reviewed research, and proven pharmacology. The new ADHD test adds to the company's treatment decision support products that include GeneSightRx Psychotropic, a psychiatric pharmacogenomic product that tests important genomic variants affecting metabolism to psychiatric medications for individual patients.

ADHD diagnoses increased 66 percent from 6.2 million in 2000 to 10.4 million in 2010, according to a study published in the March/April 2012 issue of Academic Pediatrics. ADHD is the most common childhood disorder and can continue into adulthood. Symptoms of ADHD include an inability to stay focused or pay attention, difficulty controlling behavior, and hyperactivity.

"ADHD is a neurobehavioral disorder affecting millions of children and adults. With the introduction of GeneSightRx ADHD, clinicians now have an objective, evidence-based tool for individualizing ADHD medications," said James S. Burns, president and CEO of AssureRx Health."Our goal is to build a portfolio of innovative pharmacogenomic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders."

When a clinician orders the test, a DNA sample is taken from the patient with a simple, non-invasive cheek swab. The specimen is sent overnight to AssureRx Health's CLIA-certified and CAP-accredited laboratory. The ordering clinician receives the patient report via a secure online portal that presents the patient's genomic information in an easy-to-read and clinically actionable format.

About GeneSightRx

GeneSightRx is a laboratory developed genomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSightRx report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, FDA approved manufacturer's drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenomics and GeneSightRx, please click here. Be sure to watch the educational video on our YouTube channel.

About AssureRx Health

AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping clinicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The GeneSightRx analysis is based on pharmacogenomics the study of the genomic factors that influence an individual's response to drug treatments, using FDA approved manufacturers' drug labels, scientific and clinical peer-reviewed publications, and proven pharmacology. The company was founded to commercialize industry-leading personalized medicine technology. To learn more about pharmacogenomics and GeneSightRx, visit http://www.assurerxhealth.com.

Read the original:
AssureRx Health Launches Personalized Medicine Test for ADHD

Trovagene has named Carlo Croce to serve on its scientific advisory board. Croce is director of the Human Cancer Genetics Program and the Genetics Institute at The Ohio State University, and he is John W. Wolfe Chair in Human Cancer Genetics.

Population Genetics has named Alan Schafer as its new CEO. Schafer is an adjunct professor at Imperial College London Business School and was previously the Wellcome Trust's director of science funding. Before that he served as global vice president of technology development at GlaxoSmithKline and co-founded Hexagen, a functional genomics company that was acquired by Incyte.

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

More here:
Affy Says Genotyping Arrays a Bright Spot amid Q1 Revenue Drop; Plans to Close eBioscience Buy in Q2

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

See the original post here:
Mirna Reports on Role of miR-34a in B Cell Lymphoma, Expands Planned Phase I Beyond Liver Cancer

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Read the original here:
NIH Awards $850K in Grant Funding for miRNA Drug Research in April

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Original post:
UK Team Links Sense Strand 'Mirror microRNA' in Mammalian Cells to Neuronal Function

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

See the original post:
New Products: UCSC Cancer Genomics Hub

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Read more here:
People in the News: Marc Grodman, Charles Todd, Steve Lombardi

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

View post:
Australian Project to Sequence 10K Tumors, Study Cost Effectiveness of Personalized Oncology

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Read the rest here:
Q&A: CeGaT's Saskia Biskup on Building an NGS-Based Clinical Sequencing Lab

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

See original here:
Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

The rest is here:
EdgeBio Receives CLIA Certification, Launches Clinical Exome Test

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Original post:
IP Watch: Abbott, University of Utah, Fluidigm, Roche, Quest, and Others Win US Patents

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Read more here:
New Products: Integromics' OmicsOffice; GenBank version 189

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Continue reading here:
People in the News: Sherri Bale